Breast Cancer Treatment Outcomes Across Racial Subgroups: Talazoparib Versus Chemotherapy
Posted: Friday, April 10, 2020
In the EMBRACA trial, researchers previously observed improvements in progression-free survival among both white and non-white patients with HER2-negative locally advanced, metastatic breast cancer and a germline BRCA1/2 mutation treated with talazoparib compared with physician’s choice chemotherapy. In a post-hoc analysis, Sara A. Hurvitz, MD, of the University of California Los Angeles, and colleagues, found that patient-reported outcomes also favored talazoparib regardless of racial subgroup. The findings were originally slated for presentation at the 2020 NCCN Annual Conference (Abstract CLO20-039) but published in the JNCCN–Journal of the National Comprehensive Cancer Network.
Using the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30, the researchers recorded patient-reported outcomes at baseline, the start of each treatment cycle, and the end of treatment. Higher scores on the questionnaire indicated better functioning and quality of life or worse symptom severity. The study team compared overall score change from baseline and the time to definitive meaningful deterioration between racial subgroups.
The baseline scores for patient-reported outcomes were similar between the talazoparib and chemotherapy groups. The overall change from baseline in quality of life was statistically significant and favored talazoparib for both white (P = .003) and non-white (P = .002) subgroups. Similarly, a statistically significant change from baseline in patient-reported pain symptoms favored talazoparib over chemotherapy for both white (P < .001) and non-white (P = .02) patients. The researchers also observed a significantly longer delay in the time to meaningful deterioration in quality of life associated with talazoparib than chemotherapy for both white (21.1 vs. 6.3 months; P < .001) and non-white (not reached vs. 10.4 months; P = .01) patients. A longer delay in meaningful deterioration in pain symptoms also tended to favor talazoparib in both white (22.7 vs. 10.3 months; P < .001) and non-white (23.0 vs. 7.5 months; P = .22) subgroups.
Disclosure: Dr. Hurvitz has received research support from Amgen, Bayer, Daiichi Sankyo, Genentech/Roche, Immunomedics, Lilly, Macrogenics, Merrimack, Novartis, OBI Pharma, Pfizer, Pieris PUMA, Radius, Sanofi, Seattle Genetics, and Dignitana and has served as an unpaid steering committee member for Pfizer. Dr. Quek and Dr. Bhattacharyya are employees of Pfizer. Dr. Ettle has received consulting fees from Pfizer, Novartis, Lilly, Roche, and TEVA, and research support from Pfizer, Lilly, Novartis, Seattle, AstraZeneca, Roche, and Odonate. Dr. Gonçalves has received honoraria from Pfizer, Novartis, Roche, MSD, Astra Zeneca, and Celgene. Dr. Rugo has received research support from Eisai, Genentech, GlaxoSmithKline, Lilly, MacroGenics, Merck, Novartis, OBI Pharma, Pfizer, and Plexxikon and honoraria from Eli Lilly, Mylan, and Puma.
